Introduction Implementation of low-intensity, evidence-based psychological interventions can help meet the mental health and ...

First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer's Patients Treated with Anti-Amyloid ...

First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid ...

Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE ...

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary ...

Introduction Cognitive impairment is a common consequence after stroke. Intermittent theta burst stimulation (iTBS) has emerged as a promising cognitive therapy. However, traditional iTBS typically ...

-- First Patient Expected to be Dosed Next Week with Intranasal Foralumab -- PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer's Patient on Leqembi (R) (Lecanemab) Anti-Amyloid ...

Providing surgeons feedback and education on their performance significantly improved the quality of bladder cancer ...

Background Previous epidemiological studies demonstrated that premature atrial contractions (PACs) and premature ventricular ...

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction ...

We dissect Cortisol Face,' separating actual hormonal imbalance from general inflammation, and evaluate the answer and the ...

Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with ...